| Amy E Sarina, MD | |
|
2002 Medical Pkwy, Suite 235, Annapolis, MD 21401-3046 | |
| (410) 266-2770 | |
| (410) 841-6251 |
| Full Name | Amy E Sarina |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 22 Years |
| Location | 2002 Medical Pkwy, Annapolis, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326171760 | NPI | - | NPPES |
| 182936ZDYC | Other | MD | RR MEDICARE ARA PTAN |
| S645AN | Other | MD | AAD MEDICARE |
| P00897470 | Other | MD | RR MEDICARE SHIPLEYS PROVIDER PTAN |
| 182936ZD7B | Other | MD | MEDICARE PTAN - AAD S645 |
| P00897478 | Other | MD | RR MEDICARE AAD PROVIDER PTAN |
| 419952900 | Other | MD | MEDICAID - AAD SHIPLEYS |
| 9669378 | Other | MD | AAD AETNA (SHIPLEYS) |
| CN6292 | Other | MD | RR MEDICARE SHIPLEYS GROUP PTAN |
| KC46SH | Other | MD | AAD MEDICARE SHIPLEYS |
| 1073 | Other | MD | AAD |
| 3811 | Other | MD | AAD SHIPLEYS |
| 419952900 | Medicaid | MD | |
| CA1932 | Other | MD | RR MEDICARE AAD GROUP PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 0101244987 (Virginia) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | D0066121 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Anne Arundel Medical Center | Annapolis, MD | Hospital |
| Doctors' Community Hospital | Lanham, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brown, Croft, Frazier, Pa | 9537101746 | 24 |
| Luminis Health Imaging, Inc. | 8729054598 | 25 |
| Brown, Croft, Frazier, Pa | 9537101746 | 24 |
| Luminis Health Imaging, Inc. | 8729054598 | 25 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.
A Canadian expert is warning that high blood pressure during pregnancy could be an early warning that the woman is at risk of developing heart disease later on.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Clonidine Hydrochloride Injection in two dosage strengths.
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) and collaborators nationwide have found that decreased sexual satisfaction in postmenopausal women, is not clearly associated with cardiovascular disease.
AutoImmune Inc. today announced that its stockholders have voted in favor of the company's voluntary dissolution pursuant to a Plan of Complete Liquidation and Dissolution at a special meeting of stockholders held on May 11, 2010. Stockholders voted overwhelmingly in favor of the dissolution of the company pursuant to the Plan of Complete Liquidation and Dissolution, with the proposal receiving an affirmative vote from approximately 99% of the votes cast at the special meeting of stockholders.
› Verified 9 days ago
| Entity Name | Luminis Health Imaging, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366420879 PECOS PAC ID: 8729054598 Enrollment ID: O20040903000184 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.
A Canadian expert is warning that high blood pressure during pregnancy could be an early warning that the woman is at risk of developing heart disease later on.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Clonidine Hydrochloride Injection in two dosage strengths.
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) and collaborators nationwide have found that decreased sexual satisfaction in postmenopausal women, is not clearly associated with cardiovascular disease.
AutoImmune Inc. today announced that its stockholders have voted in favor of the company's voluntary dissolution pursuant to a Plan of Complete Liquidation and Dissolution at a special meeting of stockholders held on May 11, 2010. Stockholders voted overwhelmingly in favor of the dissolution of the company pursuant to the Plan of Complete Liquidation and Dissolution, with the proposal receiving an affirmative vote from approximately 99% of the votes cast at the special meeting of stockholders.
› Verified 9 days ago
| Entity Name | Brown, Croft, Frazier, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902807324 PECOS PAC ID: 9537101746 Enrollment ID: O20050527000410 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.
A Canadian expert is warning that high blood pressure during pregnancy could be an early warning that the woman is at risk of developing heart disease later on.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Clonidine Hydrochloride Injection in two dosage strengths.
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) and collaborators nationwide have found that decreased sexual satisfaction in postmenopausal women, is not clearly associated with cardiovascular disease.
AutoImmune Inc. today announced that its stockholders have voted in favor of the company's voluntary dissolution pursuant to a Plan of Complete Liquidation and Dissolution at a special meeting of stockholders held on May 11, 2010. Stockholders voted overwhelmingly in favor of the dissolution of the company pursuant to the Plan of Complete Liquidation and Dissolution, with the proposal receiving an affirmative vote from approximately 99% of the votes cast at the special meeting of stockholders.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy E Sarina, MD 2002 Medical Pkwy, Suite 235, Annapolis, MD 21401-3046 Ph: (410) 266-2770 | Amy E Sarina, MD 2002 Medical Pkwy, Suite 235, Annapolis, MD 21401-3046 Ph: (410) 266-2770 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.
A Canadian expert is warning that high blood pressure during pregnancy could be an early warning that the woman is at risk of developing heart disease later on.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Clonidine Hydrochloride Injection in two dosage strengths.
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) and collaborators nationwide have found that decreased sexual satisfaction in postmenopausal women, is not clearly associated with cardiovascular disease.
AutoImmune Inc. today announced that its stockholders have voted in favor of the company's voluntary dissolution pursuant to a Plan of Complete Liquidation and Dissolution at a special meeting of stockholders held on May 11, 2010. Stockholders voted overwhelmingly in favor of the dissolution of the company pursuant to the Plan of Complete Liquidation and Dissolution, with the proposal receiving an affirmative vote from approximately 99% of the votes cast at the special meeting of stockholders.
› Verified 9 days ago
Luqman K Dad, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy, Suite 235, Annapolis, MD 21401 Phone: 410-266-2770 Fax: 410-841-6251 | |
Dr. Quang Nguyen, Radiology Medicare: Accepting Medicare Assignments Practice Location: 2001 Medical Pkwy, Annapolis, MD 21401 Phone: 410-266-2770 Fax: 410-841-6251 | |
Dr. Mark S Radowich, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy, Suite 235, Annapolis, MD 21401 Phone: 410-266-2770 Fax: 410-841-6251 | |
Dr. Thomas B. Lank, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 122 Defense Hwy, Chesapeake Medical Imaging, Annapolis, MD 21401 Phone: 410-571-0350 Fax: 410-571-9348 | |
Dr. Frank J Groshek, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy Ste 235, Annapolis, MD 21401 Phone: 410-266-2770 Fax: 410-841-6251 | |
Dr. Mark Cameron Davis, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 845 Coachway, Annapolis, MD 21401 Phone: 952-595-1100 Fax: 612-294-4903 | |
Dr. Kerry J. Thompson, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy, Suite #235, Annapolis, MD 21401 Phone: 410-266-2770 Fax: 410-841-6251 |